|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We identified two NRAS-activating somatic mutations, Q61R and Q61K, affecting two main subpopulations in the metastasis PV1 and a BRAF alternative splicing, involving exons 4-10, in the metastasis PV2.
|
23948972 |
2013 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We found consistent BRAF and NRAS mutation status in all but one of 27 patients with multiple metastases.
|
23855428 |
2013 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Transcriptome profiling revealed that transcription factor HMGA2, previously unrecognized in melanoma pathogenesis, is significantly upregulated in primary melanoma and metastases (P-values=1.2 × 10(-7) and 9 × 10(-5)) compared with N. HMGA2 overexpression is associated with BRAF/NRAS mutations (P=0.0002).
|
23633021 |
2013 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
This study aimed to determine if BRAF and NRAS mutant and wild-type tumours differ in their site of first tumour metastasis and anatomical metastatic pathway.
|
28787433 |
2017 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This bioinformatics analysis demonstrated that stage-related prognostic DEGs, such as COL3A1, COL1A1, COL1A2, KRAS, and NRAS might play an unfavorable role in the development as well as metastasis of ovarian cancer.
|
30142790 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These patients were more likely to have brain metastases at the time of presentation with metastatic disease than their N-RAS-wild-type counterparts.
|
24588908 |
2014 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
These analyses revealed a moderate to strong phosphorylated Akt expression in 78% (21 of 27) of metastases with NRAS mutations and in 73% (54 of 74) of metastases without NRAS mutations.
|
16567976 |
2006 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Therefore, we established a large collection of patient-derived xenografts (PDXs), derived from BRAF(V600E), NRAS(Q61), or BRAF(WT)/NRAS(WT) melanoma metastases prior to treatment with BRAF inhibitor and after resistance had occurred.
|
27320919 |
2016 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The significant associations of mutations were KRAS with age less than 60 years (p = 0.041), PIK3CA with males (p = 0.032), tumor stage I-II (p = 0.013), lack of metastasis in lymph nodes (p = 0.040), NRAS with rectum (p = 0.002), and APC with T2 stage of tumor growth (p = 0.013).
|
28222664 |
2017 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The present paper describes mutational analysis by polymerase chain reaction-single-strand conformation polymorphism (PCR/SSCP) and nucleotide sequence analysis of the genes coding for the p15, p53 and N-ras proteins in 26 metastases from 25 melanoma patients.
|
8826861 |
1996 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The presence of a RAS mutation, especially a NRAS codon 61 mutation, was significantly associated with the distant metastasis.
|
24820091 |
2014 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The cyclin D1 (CCND1) mRNA level decreased in lesions with multiple metastases and was correlated with both the mRNA levels and mutation state of BRAF and NRAS genes.
|
23001925 |
2012 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The absence of PTEN leads to caveolin-1 (CAV1)-dependent β-catenin transcriptional modulation in vitro, cooperates with NRAS(Q61K) to initiate melanomagenesis in vivo and induces efficient metastasis formation associated with E-cadherin internalization.
|
26307673 |
2015 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The NRAS codon 61 mutation in follicular carcinomas was positively associated with distant metastases through the entire clinical course of the patients (p<0.05), and RAS mutations were associated with poor overall patient survival (p<0.05).
|
22650231 |
2012 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
|
28323937 |
2017 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Stage I-III patients with PIK3CA or NRAS mutations developed more distant metastases (3-year risk in PIK3CA mutated and wild type patients: 23.3% vs 11.5%, P = 0.03; multivariate Hazard ratio (HR) = 3.129, P = 0.003; 3-year risk in NRAS mutated and wild type patients: 40.0% vs 12.2%, P = 0.012; multivariate HR = 5.152, P = 0.003).
|
29666387 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
|
27299298 |
2016 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Patients with BRAF or NRAS mutations were more likely than WT patients to have central nervous system involvement at the time they were diagnosed with distant metastatic disease.
|
22180178 |
2012 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Patients and methods In our retrospective analysis we analysed mutational status of BRAF, NRAS and c-KIT in 230 pathological samples of patients who were intended to be treated with systemic therapy due to metastatic disease at the Institute of Oncology Ljubljana between 2013 and 2016.
|
30210039 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Patient-derived cultures of the BRAF mutant/NRAS wild type and BRAF wild type/NRAS mutant metastases showed more homogeneous single-cell gene expression patterns with gene expression modules for proliferation and ABC transporters.
|
27903987 |
2017 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Only 31.3% of BRAF mutant- and 50% of NRAS mutant cases maintained the MAF profile of the primary in metastasis.
|
31391014 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Occurrence of ocular melanoma thirteen years after skin melanoma: two separate primaries or metastatic disease? A case solved with NRAS and CDKN2A (INK4A-ARF) mutational analysis.
|
18205010 |
2008 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Mutations were observed in 63% of metastases (48% BRAF; 15% NRAS), a nonsignificant increase in mutation frequency after progression from primary melanoma.
|
22614978 |
2012 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mutations in BRAF and NRAS genes were mutually exclusive in all but one case, and were maintained from primary tumors through their metastases.
|
16098042 |
2005 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mutational status for KRAS, NRAS, and BRAF genes should be performed on all colorectal carcinoma (CRC) specimens in order to guide targeted therapy selection for metastatic disease.
|
31290252 |
2019 |